Abstract
One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.
Original language | English |
---|---|
Pages (from-to) | 437-440 |
Number of pages | 4 |
Journal | Movement Disorders |
Volume | 9 |
Issue number | 4 |
DOIs | |
Publication status | Published - 1994 |
Keywords
- Motor symptoms
- Naltrexone
- Parkinson's disease
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)